Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the availability of proxy materials for its upcoming 2025 Annual Meeting of Stockholders, scheduled for October 17, 2025 at 10:00 a.m. Eastern Time. The meeting will be held virtually.
Stockholders of record as of August 18, 2025 will receive a Notice of Internet Availability of Proxy Materials. All proxy materials, including the notice, proxy information statement, and proxy card, along with the company's audited financial statements for 2023 and 2024, can be accessed through www.proxyvote.com and the company's investor relations website.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha annunciato la disponibilità dei materiali di procura per la prossima Assemblea Annuale degli Azionisti 2025, prevista per il 17 ottobre 2025 alle 10:00 ora dell'Est. La riunione si svolgerà in modalità virtuale.
Gli azionisti registrati al 18 agosto 2025 riceveranno un Avviso di Disponibilità Internet dei Materiali di Procurazione. Tutti i materiali di procura, inclusi l'avviso, la dichiarazione informativa sui proxy e la scheda di procura, insieme ai bilanci auditati per il 2023 e 2024, possono essere consultati su www.proxyvote.com e sul sito di relazioni con gli investitori dell'azienda.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha anunciado la disponibilidad de materiales de procuración para su próxima Junta Anual de Accionistas 2025, programada para el 17 de octubre de 2025 a las 10:00 a.m. hora del Este. La reunión se celebrará de forma virtual.
Los accionistas registrados al 18 de agosto de 2025 recibirán un Aviso de Disponibilidad de Materiales de Proxy por Internet. Todos los materiales de procuración, incluido el aviso, la declaración informativa sobre la proxy y la tarjeta de proxy, junto con los estados financieros auditados de 2023 y 2024 de la empresa, pueden ser accedidos a través de www.proxyvote.com y del sitio de relaciones con inversores de la empresa.
Eagle Pharmaceuticals (OTCMKTS: EGRX)은 다가오는 2025년 주주총회를 위한 대리 자료의 이용 가능성을 발표했습니다. 회의는 2025년 10월 17일 동부 표준시 10:00에 예정되어 있으며, 회의는 온라인으로 진행됩니다.
2025년 8월 18일 기준으로 등재된 주주는 인터넷 대리자료 이용 안내를 받게 됩니다. 안내를 포함한 모든 대리 자료(공지, 대리 정보 요약 및 대리 카드)와 회사의 2023년 및 2024년 감사 재무제표는 www.proxyvote.com 및 회사의 투자자 관계 웹사이트에서 열람할 수 있습니다.
Eagle Pharmaceuticals (OTCMKTS : EGRX) a annoncé la disponibilité des documents de procuration pour sa prochaine Assemblée générale annuelle des actionnaires 2025, prévue le 17 octobre 2025 à 10h00, heure de l'Est. La réunion se tiendra virtuellement.
Les actionnaires inscrits au 18 août 2025 recevront un Avis de Disponibilité Internet des documents de procuration. Tous les documents de procuration, y compris l'avis, la déclaration d’informations sur les procurations et la carte de procuration, ainsi que les états financiers audités de l’entreprise pour 2023 et 2024, peuvent être consultés sur www.proxyvote.com et sur le site des relations investisseurs de l’entreprise.
Eagle Pharmaceuticals (OTCMKTS: EGRX) hat die Verfügbarkeit von Proxy-Unterlagen für die bevorstehende Hauptversammlung der Aktionäre 2025 bekannt gegeben, die am 17. Oktober 2025 um 10:00 Uhr Ostzeit stattfindet. Die Versammlung wird virtuell abgehalten.
Aktieninhaber, die am 18. August 2025 im Aktienregister stehen, erhalten eine Benachrichtigung über die Internet-Verfügbarkeit der Proxy-Unterlagen. Alle Proxy-Unterlagen, einschließlich der Benachrichtigung, der Proxy-Informationsmitteilung und der Proxy-Karte, sowie die geprüften Jahresabschlüsse des Unternehmens für 2023 und 2024, sind über www.proxyvote.com und die Investor-Relations-Website des Unternehmens zugänglich.
Eagle Pharmaceuticals (OTCMKTS: EGRX) أعلنت عن توافر مواد التفويض لجمعيتها العامة السنوية القادمة لعام 2025، المقررة في 17 أكتوبر 2025 الساعة 10:00 صباحاً بتوقيت الساحل الشرقي. ستُعقد الاجتماعات افتراضياً.
سيستلم مالكو الأسهم المسجلون اعتباراً من 18 أغسطس 2025 إشعاراً بتوافر مواد التفويض عبر الإنترنت. يمكن الوصول إلى جميع مواد التفويض، بما في ذلك الإشعار، وبيان معلومات التفويض، وبطاقة التفويض، إلى جانب البيانات المالية المُراجَعة للشركة لعامي 2023 و2024، من خلال www.proxyvote.com وموقع علاقات المستثمرين بالشركة.
Eagle Pharmaceuticals（OTCMKTS: EGRX） 已宣布其即将举行的 2025 年股东大会的代理资料现已可用，会议定于 2025 年 10 月 17 日美国东部时间上午 10:00 举行。会议将以虚拟方式举行。
截至 2025 年 8 月 18 日在册的股东将收到代理资料的互联网获取通知。所有代理资料，包括通知、代理信息声明和代理卡，以及公司 2023 年和 2024 年的经审计财务报表，均可通过 www.proxyvote.com 及公司的投资者关系网站获取。
- None.
- None.
WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time.
The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, are available at www.proxyvote.com and https://investor.eagleus.com/events-presentations. In addition, the Company’s audited financial statements as of and for the years ended December 31, 2024 and 2023, are available at https://investor.eagleus.com/events-presentations.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When is Eagle Pharmaceuticals (EGRX) 2025 Annual Meeting of Stockholders?
What is the record date for Eagle Pharmaceuticals' 2025 Annual Meeting?
Where can I find Eagle Pharmaceuticals' proxy materials and financial statements?
What years of audited financial statements has Eagle Pharmaceuticals made available?
